WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Directors. During a career of nearly 30 years with Gilead, Dr. Bischofberger oversaw the development of more than 25 medicines that transformed the treatment of serious pathogens or diseases including HIV, HCV and lymphoma.
- Deal extends reach of Morphic discovery across all known human integrins
- Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research
- Collaboration facilitated by Johnson & Johnson Innovation, Boston
WALTHAM, Mass. – February 21, 2019 – Morphic Therapeutic (Morphic), a biotechnology company developing oral integrin therapies, announced today that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics for patients with conditions not adequately addressed by current therapies. Johnson & Johnson Innovation LLC facilitated the transaction. The collaboration focuses on several undisclosed integrin targets and will explore both inhibitors and activators of integrin function.
Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities
NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic Therapeutic, a biotechnology company developing oral integrin therapies, announced today that the companies have entered into a research and development collaboration designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.
Series B financing led by Omega Funds and Novo Holdings
Financing to enable the initiation of IND-enabling and clinical studies in 2019
WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it has completed a $80 million Series B financing to fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.
Check out Morphic’s recent joint publication with Springer lab and see how the binding affinity and kinetics of pro-TGFβ to integrin αvβ6 are regulated by the receptor conformation. https://timothyspringer.org/publications/high-integrin-alphavbeta6-affinity-reached-hybrid-domain-deletion-slows-ligand-binding
Here’s to the fact that all great things start the same.
Despite all of Tim Springer’s achievements – tributes, awards, companies, and other accomplishments – his latest philanthropic venture launches grand in vision but step-by-step and local in action.
Integration between biotech and Big Pharma has never before looked like this.
Both Astra Zeneca and Morphic Therapeutic decided to forego an originally planned divider wall. As far as we know, this creates the 1st completely integrated labs between Big Pharma and Biotech leading to valued personal interaction; and sharing of ideas, equipment, and resources.